Eastern Bankshares Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.56B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.7× Eastern Bankshares Inc. Common Stock's market cap, and Eastern Bankshares Inc. Common Stock pays the higher dividend (2.67%). Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EBC | ZBH | |
|---|---|---|
Market Cap | $4.79B | $17.56B |
Volume | 1,740,716 | 2,298,426 |
Sector | Financials | Health |
52-Week High | $23.65 | $103.98 |
52-Week Low | $16.73 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $5.07B | $24.63B |
Dividend Yield | 2.67% | 1.04% |
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
Zimmer Biomet (ZBH) trades at $91.77, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady at $8.23B for 2025, though net income margins have moderated from 13.84% in 2023 to 8.56% in 2025. The company maintains strong profitability with a 69.87% gross margin and recently announced a $0.24 quarterly dividend.
ZBH presents a mixed outlook with positive earnings momentum and analyst consensus price target of $103.11 offering 12% upside potential. However, rising debt levels and competitive pressures in medical technology pose risks. Institutional ownership trends show continued interest, with State Street increasing its position by 0.6% in Q3 2026. The stock's valuation at 22.35 P/E appears reasonable given the company's market leadership position.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →